Stock Analysts’ updated eps estimates for Wednesday, October 11th: Apogee Therapeutics (NASDAQ:APGE) had its outperform rating reaffirmed by analysts at Wedbush. They currently have a $40.00 price target on the stock. B2Gold (NYSEAMERICAN:BTG) (TSE:BTO) was downgraded by analysts at StockNews.com from a strong-buy rating to a buy rating. Donaldson (NYSE:DCI) was upgraded by analysts at […]
Several brokerages have updated their recommendations and price targets on shares of Apogee Therapeutics (NASDAQ: APGE) in the last few weeks: 8/8/2023 – Apogee Therapeutics is now covered by analysts at TD Cowen. They set an “outperform” rating on the stock. 8/8/2023 – Apogee Therapeutics is now covered by analysts at Wedbush. They set an […]